The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

Respect the role (and confidentiality) of the EAB at UCSD—and at all NCI-designated cancer centers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Over the years, I have gained extensive experience with academic cancer center External Advisory Boards, including hosting multiple EAB meetings at my own cancer center, chairing the EABs of nine other NCI designated cancer centers, and serving on many others. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
George J. Weiner, MD
Professor of internal medicine-hematology, oncology, and blood & marrow transplantation, Professor of pharmaceutical sciences and experimental therapeutics, CE Block Chair of Cancer Research, Director emeritus, University of Iowa Holden Comprehensive Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds

Adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy improved disease-free survival for patients with intermediate- or high-risk localized prostate cancer, according to the results of a multicenter clinical trial led by researchers at the Johns Hopkins University School of Medicine, Johns Hopkins Kimmel Cancer Center, Department of Radiation Oncology and Molecular Radiation Sciences, and Brady Urological Institute.
Clinical Roundup

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment. 
Byline
George J. Weiner, MD
Professor of internal medicine-hematology, oncology, and blood & marrow transplantation, Professor of pharmaceutical sciences and experimental therapeutics, CE Block Chair of Cancer Research, Director emeritus, University of Iowa Holden Comprehensive Cancer Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account